34 results about "Brown Adipocyte" patented technology

A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.

The present invention provides an application of a thermogenesis-enhancing compound to enhance the thermogenesis induced by a norepinephrine compound in brown adipocytes. Specifically, the present invention provides a use of a thermogenesis-enhancing compound for preparing a preparation or a composition. The preparation or composition is used to enhance the heat production efficiency of brown fat cells induced by NE compounds, wherein the heat production enhancing compound is selected from the group consisting of ATP compounds, ATP synthase inhibitors, or combinations thereof. The heat production enhancing compound of the present invention can significantly enhance the heat production efficiency of brown fat cells induced by norepinephrine compounds.

The application of butylenephthalide (butylidenephthalide, BP) includes using butylenephthalide (BP) to provide a kind of kit for promoting the differentiation of stem cells into brown adipocytes, and using butylenephthalide (BP) in the manufacture of A use of a medicament, wherein the medicament is used for inhibiting the accumulation of white fat, promoting the transformation of white fat into brown fat, inhibiting weight gain and / or reducing the content of triglyceride, glucose and total cholesterol in blood.

Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.

Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells.

The present invention provides new applications of miR-327 inhibitors and / or FGF10 promoters, especially the applications in the preparation of drugs for preventing and / or treating diabetes. miR-327 inhibitors and FGF10 promoters can both promote the increase of FGF10 in the stromal cell components of adipose tissue, promote the differentiation of stromal cell component adipocyte precursors into brown adipocytes, increase energy consumption, and promote fat metabolism, thereby preventing And / or the effect of treating lipodystrophy. The present invention also provides a drug for preventing and / or treating lipodystrophy, including miR‑327 inhibitor and a pharmaceutically acceptable carrier thereof.

Use of a transforming growth factor beta (TGF-Beta) signalling inhibitor for producing a population of brown adipocytes in vitro is described.

The present invention provides an application of human brown adipocyte-secreted peptide FAQPEILIGTIPGAGGTQR in the prevention and treatment of obesity; brown adipocyte-secreted peptide FAQPEILIGTIPGAGGTQR can achieve weight loss effect in obese model mice, and improve insulin sensitivity and glucose tolerance, and play a role in the prevention and treatment of obesity. At the same time, FAQPEILIGTIPGAGGTQR can also slow down the weight gain caused by high-fat diet under mild cold exposure, reduce blood sugar, blood lipid and other obesity-related abnormal metabolic indicators, and play a role in preventing obesity; therefore, the brown adipocytes secrete peptide The derivatives and drug combinations thereof have the potential to prepare polypeptide drugs for treating and preventing obesity and its complications.

The invention discloses a method for constructing a genetically engineered cell line of anti-obesity drug target UCP1, and at the same time discloses the establishment and application of a high-throughput screening model for anti-obesity drugs. It mainly involves using the CRISPR / Cas9 system to design two unique sgRNAs to knock in luciferase‑T2A‑tdTomato‑WPRE‑pA after the N-terminal ATG of the UCP1 gene in cells, especially knocking luciferase and tdTomato into immortalized brown adipocyte UCP1 The first stably transfected brown adipocyte cell line with luciferase and tdTomato inserted into the UCP1 promoter region was formed, and it was used in high-throughput screening of anti-obesity drugs, evaluation of anti-obesity drugs, and anti-obesity active substances in the body. evaluation and development of UCP1 detection kits. UCP1 is an uncoupling protein specifically expressed in brown adipose tissue and a new target for anti-obesity. The construction of this stable transgenic engineered cell line is suitable for the application of reporter genes and high-content methods, sensitive, accurate and efficient. Through flux screening, it is of great significance to obtain anti-obesity drugs that promote thermogenesis and reduce body weight.